Puma Biotechnology Inc (PBYI): Debts to Book Capitalization

The price chart for Puma Biotechnology (PBYI) reflects the dynamics of a business that dominates breast tumor treatment thanks to an exclusive patent that allows it to exercise maximum pricing power over therapy costs. The current metric stands at 0.03, while Puma Biotechnology (PBYI) seeks to overcome a dangerous reliance on a single flagship product through expansion into new markets. However, global instability and sanctions are creating significant barriers to raw material supplies and the conduct of international research.

Puma Biotechnology's reliance on the sales of a single oncology drug creates specific risks for the long-term sustainability of the business. The company's current total debt-to-equity ratio stands at 0.03, reflecting the proportion of borrowed funds within the overall asset structure and allowing investors to assess the balance between capital security and the efficiency of its utilization for company development.